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The ultimate objective of development of newer 
therapeutic alternatives is to increase efficacy and/or 
enhance safety. Historically structural changes in 
existing drugs have given rise to safer alternatives. One 
of the currently adapted strategy to enhance safety and/or 
efficacy of existing agents is  switching from existing 
racemate to one of its optical isomers and is known as  
'Chiral Switch' 1,4 which has provided safer alternatives 
to a wide range of drugs.  Since the last 20 yrs there has 
been a steady increase in the number of drugs being used 
as single enantiomers and sales for single enantiomers 
were $225 billion in 2005 which represented 37% of 
total marketed drugs.2 Similar trend is seen in new drug 
launches where the single enantiomers are steadily 
picking up at the cost of achiral drugs and racemates as 






No of new drugs 
launched
Launches of synthetic drugs
Racemates 50 30 30 22 6
Achiral drugs 70 46 50 46 28
Single enantiomers 24 20 38 40 48
1985-88 1989-92 1993-96 1997-00 2001-04
 
Figure 1
DEFINITIONS AND CHEMISTRY: 
4,5
 
Chirality is a property of an object by which the object is 
not super-imposable on its mirror image. Chiral 
compounds possess the property of handedness, i.e., they 
may be right-handed or left-handed. (Cheira in Greek 
means hand). These two - left- and right-handed - forms 
of a chiral compound are identical in their structural 
formulae but differ in spatial arrangement so that one 
form is exactly a mirror image of the other but the two 
forms are not superimposable on one another. This is 
similar to a pair of gloves, socks or hands. This existence 
of left- or right-handedness of a compound is referred to 
as chirality. The mirror images are termed enantiomers 
depicted as under in (Fig 2) 
ABSTRACT: 
During the last decade, drug chirality, more specifically the use of single enantiomers versus racemic mixtures has been in the 
forefront of discussions in scientific forums. This is because the left and right handed twins of a molecule behave quite 
differently from each other in a biological environment. This can frequently lead to an improvement in pharmacological and 
therapeutic profile of the molecule/drug. This understanding of the significance of stereochemistry coupled with advances in 
chemical technologies and further nudged by regulatory requirements has helped the increase in the development of individual 
isomers at the expense of racemic mixtures. Apart from the development of novel stereo-selective compounds, a number of 
racemates have been re-evaluated as potential single enantiomer agents with  the possibility of an improved pharmacological/ 
therapeutic profile. These have been termed as Chiral Switches and have resulted in the re-birth of a number of agents as single 
enantiomers and have provided significant improvements over the racemic drug. Economic considerations are also playing a 
part with pharmaceutical companies increasingly using chiral switching as a marketing strategy to increase the patent longevity 
and profitability period of a drug.  However, not all these switches have resulted in therapeutic superiority and in many 
instances, unpredicted adverse reactions have resulted. Before a switch to clinical use of single enantiomers is made, 
physicians should satisfy themselves from evidence based on well-conducted clinical trials that the chiral switch is cost-
effective and improves the outcomes for patients.  
Key Words: Chirality, Chiral Switch, Enantiomers 
 
Sharma et al                             Journal of Drug Delivery & Therapeutics; 2014, 4(2), 135-139 136 
© 2011, JDDT. All Rights Reserved                                           ISSN: 2250-1177                                    CODEN (USA): JDDTAO 
 
Figure 2 
Enantiomers have identical physical and chemical 
properties such as molecular weight, solubility and 
melting point. They only differ in their three-dimensional 
spatial configuration. A collection containing only one 
isomeric form of a chiral compound is termed a chirally 
pure, optically pure, or enantiomerically pure compound, 
while a collection of equal amounts of the two 
enantiomeric forms is called a racemate  
PHARMACOLOGICAL IMPLICATIONS OF 
CHIRALITY 
Chirality has wide ranging pharmacological implications 
and can dictate the pharmacodynamic and 
pharmacokinetic profile of a drug. 4,5 In a racemate, very 
often only one enantiomer is responsible for the desired 
pharmacological effect while the other may be either 
inactive(silent passenger) at best or antagonist and 
responsible for adverse effects at worst. Similarly the 
pharmacokinetic profile of a drug as racemic or as its 
enantiomer may be sufficiently different so as to 
therapeutically significant. 
CHIRAL SWITCH 
Chiral switch is defined as the development of an 
enantiomer from a previously marketed racemic drug. 
Very often the single enantiomer developed as a result of 
chiral switch has similar profile and indications as the 
parent racemate but can have important therapeutic 
benefits that could be as under. 5  
a) Increase in Selectivity and more predictable 
Pharmacodynamic profile 
b) More predictable and less complex 
concentration- effect curve 
c) Improved therapeutic index and safety 
d) Less complex pharmacokinetic profile 
e) Reduced potential for drug interactions 
Chiral separation techniques: 
6
 
Apart from the understanding of the pharmacological 
implications of chirality, the advances in technologies  
involved in the pharmaceutical processes of synthesis, 
separation and analysis have supported the cause of 
enantiomers.The development of methods for analytical 
and preparative  chiral separation have considerably 
improved over the last two decades. Methods using 
chromatographic such as gas cromatography, high-
performance liquid chromatography, supercritical fluid 
chromatography (SFC) and thin layer chromatography 
have been developed which use different principles for 
chiral separation. More recently, capillary 
electrophoresis and capillary electro-chromatography are 
also been widely used. For the separation of enantiomers 
on preparative scale liquid chromatography (LC) has 
become increasingly attractive. 
Some clinically important chiral switches: 
 The chiral switch process has given rise to a number of 
agents that have been developed as enantiomer products. 
A list of representative chiral switches is tabulated in 
Table 1 as follows. 
 
 
Table 1: A list of representative chiral switches 
Racemate Enantiomer 
developed as a result 
of Chiral Switch 
Indication Proposed Therapeutic benefit of enantiomer 
Salbutamol & 
Formoterol 
Levosalbutamol & RR, 
Formoterol 
Asthma Reduced  potential for airway hyper reactivity 7 
Oxybutynin S-Oxybutynin Urinary 
incontinence 
reduced incidence of anticholinergic side effects 8 
Doxazosin  S-Doxazosin  Benign 
Prostatic 
Hyperplasia 
Reduction in orthostatic hypotension with subsequent 





GERD Reduction of long term adverse effects like gastric 
carcinoids and entero-chromaffin like cell hyperplasia. 10 
Cisapride Norcisapride Nocturnal 
heartburn 
Minimal interaction with azoles/macrolides and a reduced 
occurrence of cardiotoxicity.11 
Zopiclone Eszopiclone Insomnia   Lesser incidence of residual hang overs as compared to 
the raceme. 12 
Amlodipine (S)-amlodipine:  Hypertension Reduction in side effects including ankle edema 13. 
Fluoxetine  (S)-fluoxetine  Prophylaxis 
of migraine. 
An earlier and greater reduction in attack frequency 14 
Ketoprofen Dexketoprofen. Management 
of pain 
More rapid absorption and onset of action and hence has a 
reduced potential for causing gastric ulceration .15 
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Bupivacaine Levobupivacaine Local 
anaesthesia 
The single levo-enantiomer results in a similar clinical 
profile as racemic bupivacaine with the added benefit of 
reduction in cardiotoxicity. 16 
Atracurium Cisatracurium Muscle 
relaxant 
 
The dose requirement Cisatracurium is much lower as 
compared to atracurium thereby reducing the formation of 
laudanosine, a metabolite implicated in inducing seizures. 
17 
Ketamine Esketamine. General 
anaesthesia 
A much smoother emergence from anaesthesia, a more 
intense postoperative analgesia and a more rapid recovery 
of CNS functions. The incidence of psychotomimetic 
phenomenon is also significantly less after S-ketamine as 





Allergy A smaller volume of distribution, passage through the 
Blood Brain Barrier of the enantiomer is much lesser and 
also its low cerebral receptor binding makes it more 





metoprolol:   
Hypertension S-isomers of atenolol and metoprolol retain their cardio-
selectivity even at high doses as the beta-2-blocking R-
isomer is absent 22. Particularly of importance in 
asthmatics, smokers, COPD patients and diabetics. 
 
  
DOES TURNING CHIRAL ALWAYS BENEFIT? 
Not all of the Chiral switches led to a superior substitute. 
Some chiral switching has resulted in unpredicted 
toxicity leading to halt in the development of the 
enantiomer   or even its withdrawal from the market. 
23Fenfluramine is a racemic drug which was used as an 
appetite suppressant. The combination of fenfluramine 
and the achiral anti-obesity drug phentermine 'Fen-phen,’ 
was at one time widely used for weight loss. When 
dexfenfluramine, the S-enantiomer, came to the market 
in 1996, widespread replacement of this new compound 
was done in the belief that the dextro isomer would be 
safer. However as realised later, the cardiac adverse 
effects of fenfluramine  were retained in the dextro 
isomer leading consequently, to the withdrawal of both 
fenfluramine and dexfenfluramine in 1997.24 Similarly 
the S-isomer of sotalol increased mortality in patients 
with myocardial infarction as compared to the racemate 
and investigations were prematurely terminated. 25 
Development of single beta-blocking R,R-stereoisomer, 
named dilevalol, of labetalol was halted due to 
hepatotoxic adverse effect. 26 During the Phase II trials, 
the R enantiomer of fluoxetine, showed a statistically 
significant prolongation of cardiac repolarization which 
led to a halt in the development of the enantiomer. 27 
REGULATORY ISSUES ON CHIRALITY 
At present none of the major regulatory authorities have 
an absolute  requirement for the development of single 
enantiomer drugs and the decision regarding the 
stereoisomeric form, i.e. single enantiomer or racemic 
mixture, to be developed is left to the sponsor/innovator 
of the compound . However this decision should be a 
conscious and a deliberate one and should incorporate 
detailed scientific justification based on quality, safety 
and efficacy, together with the risk-benefit ratio.   The 
FDA (USA) and the EMEA mandate that the properties 
of each enantiomer in a racemic molecule, should be 
studied separately before a decision is taken to market 
the drug as one of the enantiomers or as a mixture28,29. 
Rather than using chiral synthetic drugs as racemates in 
the first instance, the activities and toxicities of the 
enantiomers require to be tested individually. Similarly 
the regulatory authorities in Japan require that a method 
to discriminate between enantiomers should be 
investigated and the ratio of the enantiomers in the 
racemic mixture be determined 30. The responsibility lies 
with the drug developer to provide a justification based 
on scientific evidence if a racemate is sought to be 
developed instead of a single enantiomer. When single 
enantiomers are developed from previously marketed 
racemates the regulatory bodies permit bridging studies 
between the original and new submission. Because of 
this encouragement provided by regulatory attitudes, and 
ably supported by technological developments, the 
number of new chiral chemical entities as single 
stereoisomers submitted for approval to regulatory 
bodies has increased as compared to the racemic 
mixtures.  
ECONOMIC CONSIDERATIONS IN CHIRAL 
SWITCHES:  
The development of chiral switches while certainly may 
be based on sound pharmacological and therapeutic 
rationale, economic considerations are also a guiding 
force behind the exercise. Development of a new drug 
today is a high risk business and only about one drug 
discovery project in 50 managing to reach its goal of 
putting a new drug on the market.31 Not surprisingly, the 
rate of development of new agents is declining, for 
example the US FDA approved only 29 new chemical 
entities in 2008 32 which is one of the lowest number in 
the last 30 years. The situation is compounded by the fact 
that research and development costs are increasing, 
having doubled over the last fifteen years, with the cost 
estimates of bringing a drug to market reported to be 
$ 802 million and ever growing. 33 Moreover, drug 
development time is now so long that the average 
effective patent life of a “new” agent is only 10-12 years. 
In this scenario developing an enantiomer from a 
racemic compound is comparatively easier and obtaining 
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marketing approval usually requires relatively few new 
studies as has been mentioned above. 
 Another commercially driven reason for chiral switches 
is the impending expiry of the patents of some highly 
successful racemic drugs with estimated market worth of 
billions 33. The chiral switch process is increasingly 
being seen as a strategy to extend the profitable life of a 
pharmaceutical bestseller, and may result in increasing 
the patent life times and consequently provide an 
advantage against generic competition 34. The single 
enantiomer can be ready for launch before the patent for 
the racemate expires and before the marketing of any 
generics (which tend to substantially drive down the cost 
of the racemate).  
CONCLUSION 
Drug development is becoming longer and more 
complex, while marketing is increasingly competitive. 
Differences between single enantiomers and racemates 
are bound to reach the centre stage in the fight to 
promote the 'new improved' entity (read isomer). The use 
of single enantiomers have to be in line with using drugs 
rationally35 without unduly increasing the inventory of 
the hospital pharmacy which may have far reaching 
implications on cost of health care. Nevertheless the 
increasing availability of single-enantiomer drugs 
promises to provide clinicians with safer, better-
tolerated,and more efficacious medications for treating 
patients. However when both a single enantiomer and a 
racemic formulation of a drug are available, the 
information from clinical trials and clinical experience 
should be used to decide which formulation is most 
appropriate. Introduction of a single-enantiomer 
preparation of a racemic drug should not automatically 
mean that the single enantiomer should become the 
standard of care. The health care provider is required to 
be familiar with the basic characteristics of chiral 
pharmaceuticals and the decision to use a single 
enantiomer versus a mixture of enantiomers of a 
particular drug should be made in the light of the 
available data from clinical trials and clinical experience.
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